What is the Bernard-Soulier syndrome?

Bernard-Soulier syndrome is a bleeding disorder associated with abnormal platelets, which are blood cells involved in blood clotting. In affected individuals, platelets are unusually large and fewer in number than usual (a combination known as macrothrombocytopenia).

What causes Glanzmann’s Thrombasthenia?

Glanzmann thrombasthenia is caused by the lack of a protein that is normally on the surface of platelets. This substance is needed for platelets to clump together to form blood clots. The condition is congenital, which means it is present from birth. There are several genetic abnormalities that can cause the condition.

What causes Bernard-Soulier syndrome?

Bernard–Soulier syndrome (BSS), is a rare autosomal recessive bleeding disorder that is caused by a deficiency of the glycoprotein Ib-IX-V complex (GPIb-IX-V), the receptor for von Willebrand factor.

What test would be useful in differentiating von Willebrand’s disease from Bernard-Soulier syndrome?

Low to absent response to ristocetin is a reliable indicator for the diagnosis of BSS (rules out vWD). Flow cytometry is used to confirm the diagnosis.

How is Glanzmann’s Thrombasthenia diagnosed?

Glanzmann thrombasthenia is definitively diagnosed by tests that determine if there is a deficiency of the aIIbβ3 (GPIIb/GPIIIa) receptor. These tests usually involve monoclonal antibodies and flow cytometry. Genetic tests can identify the DNA mutations responsible for the disorder.

Which of the following is associated with Glanzmann’s Thrombasthenia?

Glanzmann’s thrombasthenia is associated with abnormal integrin αIIbβ3, formerly known as glycoprotein IIb/IIIa (GpIIb/IIIa), which is an integrin aggregation receptor on platelets.

What is Glanzmanns Thrombasthenia?

Description. Collapse Section. Glanzmann thrombasthenia is a bleeding disorder that is characterized by prolonged or spontaneous bleeding starting from birth. People with Glanzmann thrombasthenia tend to bruise easily, have frequent nosebleeds (epistaxis), and may bleed from the gums.

How do you treat Glanzmann Thrombasthenia?

Platelet transfusion is the standard treatment for severe bleeding and perioperative hemostasis in patients with Glanzmann thrombasthenia. A hematologist may be consulted for transfusion recommendations.

What happens with Bernard-Soulier syndrome?

Bernard-Soulier syndrome (BSS) is a rare inherited disorder of blood clotting (coagulation) characterized by unusually large platelets, low platelet count (thrombocytopenia) and prolonged bleeding time (difficulty in clotting). Affected individuals tend to bleed excessively and bruise easily.

How do you treat Bernard-Soulier?

There is no specific treatment for Bernard-Soulier syndrome. Patients should avoid any drugs which may interfere with clot formation, such as aspirin, ibuprofen, and naproxen. Severe bleeding episodes may require platelet and blood transfusions.

How rare is Glanzmann’s thrombasthenia?

Glanzmann thrombasthenia is a rare disorder that affects males and females in equal numbers. The symptoms of this disease are usually apparent at birth (neonates) or during infancy. Approximately 500 cases have been reported, but many cases have probably not been reported.

Which of the following is characteristic of Bernard-Soulier syndrome?

What is Bernard Soulier syndrome and Glanzmann-GT?

The inherited platelet glycoprotein deficiencies, Glanzmann thrombasthenia (GT) and Bernard Soulier syndrome (BSS) are rare but important long‐term bleeding disorders. Once diagnosed, affected patients should be referred to a specialist centre for bleeding disorders for general advice and ongoing management.

What is Glanzmann thrombasthenia?

Summary Summary. Glanzmann thrombasthenia (GT) is a rare inherited blood clotting disorder that is present at birth. It is characterized by the impaired function of specialized blood cells, called platelets, that are essential for proper blood clotting. Signs and symptoms vary greatly from person to person.

What was Bernard and Soulier’s ( 1948) theory of bleeding disorder?

Thirty years later, Bernard and Soulier ( 1948) described a bleeding disorder characterised by a prolonged bleeding time and the presence of a macro-thrombocytopenia.

When was NovoSeven RT approved for the treatment of Glanzmann’s disease?

July 2014, NovoSeven RT was approved for the treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets. National Library of Medicine Drug Information Portal